PBM Latest Headlines

Psyence Biomedical Corrects Technical Error in 2023 Equity Incentive Plan

at www.tipranks.com (Fri, 5-Jun 5:26 PM)

Psyence BioMed Advances Psilocybin Therapy With First Patient Dosed in Phase IIb Cancer Adjustment Disorder Trial

Market Chameleon (Thu, 23-Apr 7:06 AM)

Psyence BioMed Emerges as the World's Only Licensed Source for Pharmaceutical-Grade Ibogaine: A Strategic Edge in a Bottlenecked Market

Market Chameleon (Mon, 20-Apr 10:30 AM)

Psyence BioMed Rises on U.S. Executive Interest in Ibogaine Research—Leadership in Ethical Supply and GMP Manufacturing Sets Firm Apart

Market Chameleon (Fri, 17-Apr 10:29 AM)

Executive Action Spurs Interest in Psyence BioMed's Ibogaine Platform: GMP Manufacturing and Ethical Sourcing Set Company Apart

Market Chameleon (Fri, 17-Apr 9:42 AM)